Here are the DEF 14A proxy statements from Ernexa Therapeutics Inc. (ERNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. is asking stockholders to elect five directors, ratify Haskell & White LLP as auditor, and approve a new 2026 Omnibus Equity Incentive Plan at its virtual 2026 annual meeting on July 1, 2026, at 11:00 a.m. Eastern Time.
Holders of Ernexa common stock as of May 6, 2026, when 1,166,333 shares were outstanding, may vote online, by phone, by mail, or electronically during the meeting. The proxy details board structure, committee responsibilities, governance policies, and significant ownership, including a 32.53% stake held by Charles Cherington.
The filing also outlines executive pay, with 2025 total compensation of $888,813 for CEO Sanjeev Luther and $329,372 for Senior Vice President of Finance Sandra Gurrola, plus equity incentive arrangements and severance and change-in-control protections.